Literature DB >> 8406197

Histologic correlates of progression-free interval and survival in ovarian clear cell adenocarcinoma.

A W Kennedy1, C V Biscotti, W R Hart, L J Tuason.   

Abstract

Unlike other ovarian epithelial cancers, histologic measures of differentiation of ovarian clear cell adenocarcinoma have not been found to be reliable predictors of progression-free interval and survival. Forty-two consecutively treated patients with pure ovarian clear cell adenocarcinoma were identified and all histologic materials were reviewed. The following histologic features were assessed: architectural pattern (tubular/tubulocystic, papillary, solid, and mixed), average and maximal mitotic activity per 10 high-power fields (hpf's), percentage of cells with clear cytoplasm, and nuclear grading (both Fuhrman et al.'s (Am. J. Surg. Pathol. 6, 655-663, 1982) and Christopherson et al.'s (Cancer 49, 1511-1523, 1982) methods). Surgical stage was most predictive of survival (P < 0.01) and subsequent comparisons using Cox proportional hazards modeling were adjusted for Stages III and IV. Greater than six mitotic figures per 10 hpf's predicted a poorer survival (P = 0.05) but was not predictive of progression-free interval (P = 0.28). Survival and progression-free interval in patients with tumors of mixed architectural pattern tended to be shorter than those for patients where one type did predominate, but this was not statistically significant (P = 0.06). The tubulocystic pattern was not predictive of patient outcome nor was either method of nuclear grading. Stage and average mitotic activity seem to be the best predictors of survival for patients with ovarian clear cell adnocarcinoma, while architectural pattern and nuclear grading are not as reliable.

Entities:  

Mesh:

Year:  1993        PMID: 8406197     DOI: 10.1006/gyno.1993.1221

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Prognostic value of nuclear morphometry in patients with TNM stage T1 ovarian clear cell adenocarcinoma.

Authors:  C Q Liu; H Sasaki; M T Fahey; A Sakamoto; S Sato; T Tanaka
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

2.  Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer.

Authors:  Sou Hirose; Hiroshi Tanabe; Youko Nagayoshi; Yukihiro Hirata; Chikage Narui; Kazuhiko Ochiai; Seiji Isonishi; Hirokuni Takano; Aikou Okamoto
Journal:  J Gynecol Oncol       Date:  2018-02-06       Impact factor: 4.401

Review 3.  Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review.

Authors:  Tsukuru Amano; Tokuhiro Chano; Fumi Yoshino; Fuminori Kimura; Takashi Murakami
Journal:  Healthcare (Basel)       Date:  2019-07-30

4.  An immature inhibin-α-expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis.

Authors:  Shinya Kusumoto; Masako Kurashige; Kenji Ohshima; Shinichiro Tahara; Takahiro Matsui; Satoshi Nojima; Satoshi Hattori; Eiichi Morii
Journal:  Cancer Med       Date:  2021-02-20       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.